{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:58:23Z","timestamp":1777996703094,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejca.2022.12.027","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T20:56:39Z","timestamp":1673470599000},"page":"57-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial"],"prefix":"10.1016","volume":"182","author":[{"given":"Xuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bixia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xieqiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ChuanLiang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.12.027_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2407-11-85","article-title":"Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases[J]","volume":"11","author":"Chi","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2022.12.027_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/srep31432","article-title":"Acral melanoma in Chinese: a clinicopathological and prognostic study of 142 cases[J]","volume":"6","author":"Lv","year":"2016","journal-title":"Sci Rep"},{"issue":"20","key":"10.1016\/j.ejca.2022.12.027_bib3","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma[J]","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2022.12.027_bib4","first-page":"1968","article-title":"Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin[J]","volume":"60","author":"Bastian","year":"2000","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2022.12.027_bib5","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0002-9440(10)63536-5","article-title":"Classifying melanocytic tumors based on DNA copy number changes[J]","volume":"163","author":"Bastian","year":"2003","journal-title":"Am J Pathol"},{"issue":"9","key":"10.1016\/j.ejca.2022.12.027_bib6","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.annonc.2020.05.031","article-title":"Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients[J]","volume":"31","author":"Nakamura","year":"2020","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2022.12.027_bib7","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1158\/1078-0432.CCR-19-3922","article-title":"Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial[J]","volume":"26","author":"Tang","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7653","key":"10.1016\/j.ejca.2022.12.027_bib8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes[J]","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ejca.2022.12.027_bib9","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1007\/s12094-017-1685-3","article-title":"Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America[J]","volume":"19","author":"Castaneda","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ejca.2022.12.027_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.med.57.121304.131306","article-title":"Angiogenesis[J]","volume":"57","author":"Folkman","year":"2006","journal-title":"Annu Rev Med"},{"issue":"6","key":"10.1016\/j.ejca.2022.12.027_bib11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.seminoncol.2007.09.009","article-title":"Angiogenesis in melanoma[J]","volume":"34","author":"Mahabeleshwar","year":"2007","journal-title":"Semin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2022.12.027_bib12","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/ijc.25963","article-title":"VEGFR-2 expression in human melanoma: revised assessment[J]","volume":"129","author":"Molhoek","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2022.12.027_bib13","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.2147\/OTT.S175507","article-title":"Apatinib mesylate tablet in the treatment of advanced malignant melanoma[J]","volume":"11","author":"Yang","year":"2018","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.ejca.2022.12.027_bib14","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/cei.12069","article-title":"Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in\u00a0vivo","volume":"172","author":"Yasuda","year":"2013","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.ejca.2022.12.027_bib15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study[J]","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2022.12.027_bib16","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1007\/s12094-017-1685-3","article-title":"Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America","volume":"19","author":"Castaneda","year":"2017","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2022.12.027_bib17","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s12094-019-02033-x","article-title":"Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma","volume":"21","author":"Castaneda","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ejca.2022.12.027_bib18","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13046-021-02069-4","article-title":"Apatinib triggers autophagic and apoptotic cell death via VEGFR2\/STAT3\/PD-L1 and ROS\/Nrf2\/p62 signaling in lung cancer","volume":"40","author":"Xie1","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.12.027_bib19","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0640","article-title":"Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung cancer","volume":"7","author":"Zhao","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2022.12.027_bib20","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.20.01920","article-title":"Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase II trial","volume":"38","author":"Lan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.12.027_bib21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jtho.2020.10.002","article-title":"Camrelizumab plus apatinib in extensive-stage sclc (PASSION): a multicenter, two-stage, phase 2 trial","volume":"16","author":"Fan","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.12.027_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000696","article-title":"Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial","volume":"8","author":"Liu","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"32","key":"10.1016\/j.ejca.2022.12.027_bib23","first-page":"2987","article-title":"Axitinib in combination with toripalimab, a humanized immunoglobulin G 4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial","volume":"37","author":"Sheng","year":"2019","journal-title":"Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.12.027_bib24","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.12.027_bib25","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/jnci\/djz005","volume":"111","author":"Yeh","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"7653","key":"10.1016\/j.ejca.2022.12.027_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejca.2022.12.027_bib27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.ejca.2022.12.027_bib28","doi-asserted-by":"crossref","first-page":"76e84","DOI":"10.1016\/j.lungcan.2020.04.009","article-title":"Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: do they have a role in non-oncogene- addicted non-small cell lung cancer?","volume":"144","author":"Popat","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2022.12.027_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117106","article-title":"Therapeutic potentials of Apatinib in cancer treatment: possible mechanisms and clinical relevance","volume":"241","author":"Fathi Maroufi","year":"2020","journal-title":"Life Sci"},{"issue":"3","key":"10.1016\/j.ejca.2022.12.027_bib30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/CMR.0000000000000809","article-title":"Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy","volume":"32","author":"Zhou","year":"2022","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.ejca.2022.12.027_bib31","first-page":"565","article-title":"Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study","volume":"22","author":"Zhou","year":"2022","journal-title":"MC Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2022.12.027_bib32","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.tranon.2019.02.007","article-title":"A phase ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151)","volume":"12","author":"Lu","year":"2019","journal-title":"Transl Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923000035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923000035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:39:39Z","timestamp":1760733579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923000035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":32,"alternative-id":["S0959804923000035"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.12.027","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}